YahooSeptember 4, 2026 at 5:02 AM NYLast Month
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
170-Page Report Tracks Intellia and Regeneron's Nex-Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR TreatmentDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- "Hereditary Transthyretin Amyloidosis - Market Insight, Epidemiology, and Market Forecast - 2036" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of hATTR, its historical and forecasted epidemiology, and market trends
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
